share_log

Mizuho Maintains Outperform on Biogen, Lowers Price Target to $207

Benzinga ·  Nov 21, 2024 21:08  · Ratings

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $251 to $207.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment